Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Chubb
Merck
Federal Trade Commission
Express Scripts
McKesson
Accenture
Cantor Fitzgerald
Baxter

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018965

« Back to Dashboard
NDA 018965 describes NAPROSYN, which is a drug marketed by Atnahs Pharma Us and is included in two NDAs. It is available from four suppliers. Additional details are available on the NAPROSYN profile page.

The generic ingredient in NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Seventy-one suppliers are listed for this compound. Additional details are available on the naproxen profile page.

Summary for NDA: 018965

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Analgesics
Anti-inflammatory Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 018965

Suppliers and Packaging for NDA: 018965

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NAPROSYN
naproxen
SUSPENSION;ORAL 018965 NDA Key Therapeutics, LLC 70868-200 70868-200-16 473 mL in 1 BOTTLE (70868-200-16)
NAPROSYN
naproxen
SUSPENSION;ORAL 018965 NDA Key Therapeutics, LLC 70868-700 70868-700-16 473 mL in 1 BOTTLE (70868-700-16)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION;ORALStrength25MG/ML
Approval Date:Mar 23, 1987TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 018965

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Atnahs Pharma Us
NAPROSYN
naproxen
SUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
Atnahs Pharma Us
NAPROSYN
naproxen
SUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
Atnahs Pharma Us
NAPROSYN
naproxen
SUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
Atnahs Pharma Us
NAPROSYN
naproxen
SUSPENSION;ORAL018965-001Mar 23, 1987► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
US Department of Justice
Cantor Fitzgerald
Dow
Novartis
Federal Trade Commission
Moodys
Fuji
Healthtrust
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot